Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- New England Cancer Specialists - Kennebunk — Kennebunk, Maine
- Penobscot Bay Medical Center — Rockport, Maine
- MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
- New England Cancer Specialists - Topsham — Topsham, Maine
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Maine: - Lafayette Family Cancer Center-EMMC — Brewer, Maine
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- Lafayette Family Cancer Center-EMMC — Brewer, Maine
- MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
- MaineHealth LincolnHealth Hospital — Damariscotta, Maine
- Penobscot Bay Medical Center — Rockport, Maine
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Maine: - MaineHealth Maine Medical Center - Portland — Portland, Maine
- MaineHealth Cancer Care Center of York County — Sanford, Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Maine: - New England Cancer Specialists — Scarborough, Maine
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Maine: - New England Cancer Specialists — Scarborough, Maine
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Maine: - New England Cancer Specialists ( Site 0051) — Westbrook, Maine
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- Lafayette Family Cancer Center-EMMC — Brewer, Maine
- MaineHealth Maine Medical Center- Scarborough — Scarborough, Maine
- MaineHealth Cancer Care and IV Therapy - South Portland — South Portland, Maine
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Maine: - New England Cancer Specialists — Scarborough, Maine
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Maine: - Harold Alfond Center for Cancer Care — Augusta, Maine
- MaineHealth Waldo Hospital — Belfast, Maine
- MaineHealth Maine Medical Center - Biddeford — Biddeford, Maine
- MaineHealth Cancer Care and IV Therapy - Brunswick — Brunswick, Maine
- Mid Coast Hospital — Brunswick, Maine
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Maine: - Massive Bio SYNERGY-AI site — Scarborough, Maine
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Maine: - Central Maine Medical Center — Lewiston, Maine